Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Cutaneous B Cell Lymphomas”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Large-scale testing (Phase 3)UnknownNCT02867553
What this trial is testing

Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions

Who this might be right for
Indolent Cutaneous B Cell Lymphomas
CHU de Reims 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Early research (Phase 1)Study completedNCT00963274
What this trial is testing

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Who this might be right for
LeukemiaLymphoma
Virginia Commonwealth University 18
Not applicableActive Not RecruitingNCT07310745
What this trial is testing

Low Dose Radiotherapy in Primary Indolent Cutaneous B-cell Lymphoma

Who this might be right for
Primary Indolent Cutaneous B-cell Lymphoma
Azienda USL Reggio Emilia - IRCCS 52
Not applicableStudy completedNCT00398372
What this trial is testing

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Who this might be right for
Lymphoma, Non-HodgkinLymphomas: Non-HodgkinLymphomas: Non-Hodgkin Cutaneous Lymphoma+6 more
Stanford University 500
Testing effectiveness (Phase 2)Study completedNCT00406809
What this trial is testing

ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Chronic Lymphoid LeukemiaLymphoid MalignanciesNon-Hodgkin's Lymphoma+3 more
AbbVie (prior sponsor, Abbott) 81
Testing effectiveness (Phase 2)WithdrawnNCT00837174
What this trial is testing

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Who this might be right for
Non-Hodgkin Lymphoma
The Methodist Hospital Research Institute
Not applicableLooking for participantsNCT06860880
What this trial is testing

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Who this might be right for
Indolent LymphomasLymphomaChronic Lymphocytic Leukemia+6 more
UNC Lineberger Comprehensive Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT01994382
What this trial is testing

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Who this might be right for
Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)+2 more
Alexion Pharmaceuticals, Inc. 260
Early research (Phase 1)Study completedNCT00005580
What this trial is testing

Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Virginia Commonwealth University 54
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
24